Why Are So Many Tests Needed for Blood Disorders? An Expert Explains 6 Core Tests and What Each One Tells Us

Summary: Many patients and families wonder why the diagnostic process for a blood disorder may involve blood tests, bone marrow aspiration, flow cytometry, chromosome analysis, FISH, genetic testing, and more. Are these tests repeating the same thing? What does each one actually tell the doctor? Drawing on her clinical experience, Dr. Chunrong Tong of Beijing GoBroad Boren Hospital explains the MICM integrated diagnostic approach and introduces six core laboratory methods - morphology, pathology, flow cytometry, chromosome karyotyping, FISH, and genetic testing. Understanding how these methods complement one another can make it easier to see why each test may matter for diagnosis, treatment planning, and response assessment.

During the diagnostic process for a blood disorder, many families ask the same question: why are so many tests necessary? There may be blood draws, bone marrow procedures, and repeated samples sent to different laboratories - but what is each test looking for, and can any of them be skipped? In reality, blood disorders are usually diagnosed by combining information from multiple tests. A single method is often not enough to give a reliable answer. Here, Dr. Chunrong Tong of Beijing GoBroad Boren Hospital explains what the main laboratory tests are designed to show, along with their strengths and limitations.

When doctors order several tests for a suspected blood disorder, they are not simply repeating the same test in different forms. Each method looks at the disease from a different angle, and the results work together to build a more accurate diagnosis.

In clinical practice, evaluation is often organized across five core laboratory areas - morphology, pathology, flow cytometry, cytogenetics, and molecular diagnostics, although laboratory names may vary by hospital. Together, these areas may include cell morphology and cytochemical staining, pathology and immunohistochemistry, flow cytometry, chromosome karyotyping, FISH, genetic testing, and related methods.

Method 1: Cell Morphology and Cytochemical Staining

This is one of the most basic and fastest first steps in diagnosing hematologic malignancies. Put simply, a sample of bone marrow or blood is spread onto a glass slide, stained, and examined under a microscope so the doctor can directly assess what the cells look like.

Advantages

1. Direct and visual. Some abnormal cells have distinctive features that an experienced specialist can recognize immediately, helping narrow the diagnostic possibilities very quickly.

2. Often gives a reliable estimate of cell proportions. Morphology commonly uses the first pull of a bone marrow aspirate, which is placed directly onto a slide with minimal processing and usually less dilution by peripheral blood. Later samples used for flow cytometry, genetic testing, or chromosome analysis may come from subsequent aspirates and can sometimes show a lower proportion of abnormal cells than is actually present.

3. Provides important diagnostic clues. Morphology does more than separate normal-looking from abnormal-looking cells. It can point the team toward additional testing. For example, frequent mitotic figures may suggest rapid cell proliferation and prompt consideration of tests such as Ki-67. In some cases, blood or bone marrow smears may also show clues suggesting an infectious process.

4. Fast and relatively inexpensive. In some settings, results can be available within 20 to 30 minutes. The test uses routine stains rather than complex reagents, so it is generally one of the least costly laboratory methods.

Limitations

The biggest limitation is that morphology depends heavily on the observer's eyes and experience. Diagnostic quality can vary depending on how many different types of cases the specialist has seen.

For example, two groups of cells may look very similar under the microscope and initially resemble lymphoma, yet the final diagnosis may turn out to be epidemic hemorrhagic fever, a viral infection. Without enough experience, the appearance alone could be misleading.

Method 2: Pathology and Immunohistochemistry

Morphology looks at individual cells on a smear. Pathology and immunohistochemistry, by contrast, examine tissue - for example, a lymph node or tumor biopsy that is processed into thin sections and viewed under a microscope.

Advantages

1. Tissue is fixed promptly, helping preserve information. A biopsy specimen is usually placed in formalin soon after it is obtained, so much of the cellular and structural information is retained. Some other testing methods require more cell processing, during which certain information may be lost.

2. Can provide a more representative view of how much of the tissue is malignant. Because the pathologist examines an intact tissue section, it may more accurately show the proportion and distribution of tumor cells within that tissue.

3. Useful for cells that are difficult to obtain by aspiration, uncommon, or large. Examples include myelofibrosis, multiple myeloma, lymphoma - especially Hodgkin lymphoma (HL) - metastatic carcinoma, histiocytes, macrophages, and dendritic cells. These cells may be scarce or absent in bone marrow aspirate fluid but visible in a tissue section.

4. Shows tissue architecture and where abnormal cells are located. This is especially important in lymphoma because the pattern and organization of cells can be part of the diagnosis. Mantle cell lymphoma and follicular lymphoma, for example, have characteristic tissue patterns that can be seen on pathology sections but cannot be fully assessed by flow cytometry or genetic testing alone.

Limitations

1. Slower, and still influenced by the pathologist's experience and knowledge. Tissue must be fixed, embedded, sectioned, and stained, so the process takes longer than preparing a blood or bone marrow smear.

2. Some abnormalities are difficult to identify when tissue architecture is largely preserved, the cells show only subtle morphologic changes, or malignant cells make up only a small proportion of the sample.

3. Sampling error is possible. Some malignant cells mainly circulate in body fluids, making it difficult to obtain representative tissue. And if a biopsy misses the area containing tumor cells, the result may be negative even though disease is present elsewhere.

Method 3: Flow Cytometry (FCM)

Flow cytometry is one of the core technologies used in diagnosing hematologic malignancies. It differs from routine immunohistochemistry: conventional immunohistochemistry usually evaluates markers on tissue sections, while flow cytometry suspends cells in fluid and passes them through an instrument one by one, allowing multiple markers to be measured on each cell at the same time.

Advantages

1. Fast, practical, and information-rich. In some laboratories, a report can be available within about two hours. Tens of thousands to hundreds of thousands of cells can be assessed in one run, with many markers and multiple parameters analyzed simultaneously, giving flow cytometry high sensitivity and broad coverage.

2. Helps distinguish normal from malignant cells and identify cell lineage and maturation. For example, two patients may both have a morphology report showing '8% blasts' after treatment. Morphology alone may not tell whether those blasts are normal regenerating cells or residual leukemia cells. Flow cytometry can often make that distinction more clearly. This is one reason it is among the most widely used methods for measurable residual disease (MRD) monitoring.

3. Can help identify immunotherapy targets and monitor treatment response. Targets such as CD19, CD20, and BCMA are commonly assessed by flow cytometry to determine whether they are expressed on the abnormal cells. If the target is present, a corresponding CAR-T therapy or antibody-based treatment may be considered. Flow cytometry can also track changes during treatment, assess response, and show whether a target has been lost.

Limitations

1. It does not show tissue architecture. Because tissue is broken down into individual cells for flow cytometry, the test cannot show how those cells were originally arranged, whether they formed nodules, or whether they invaded a capsule. For diseases such as Hodgkin lymphoma (HL), where tissue structure matters, flow cytometry cannot replace pathology.

2. Some cells are easily lost during processing. Cells from diffuse large B-cell lymphoma (DLBCL), erythroblasts, and certain other cell types may break apart or be lost during staining and washing. As a result, the tumor-cell percentage reported by flow cytometry can sometimes be lower than the true proportion. For some diseases, including M6 erythroleukemia and myelodysplastic syndromes (MDS), morphology may provide advantages that flow cytometry does not.

3. Samples need to be processed quickly. Aspirates, biopsy material, and body-fluid specimens generally need prompt handling; prolonged delays can reduce cell viability and affect accuracy. This places high demands on coordination between the clinical team and laboratory.

4. The technique requires substantial expertise. Antibody selection, panel design, instrument setup, and data interpretation all require experience and specialized knowledge. The same specimen can be interpreted differently depending on technical quality and expertise.

5. Its prognostic value is generally less direct than that of chromosome and molecular genetic findings.

Method 4: Chromosome Karyotyping

Chromosomes carry much of the genetic information inside our cells. Karyotyping uses a microscope to examine chromosome number and structure - for example, whether a chromosome is missing or duplicated, or whether two chromosomes have exchanged segments in a translocation.

Advantages

1. Provides independent diagnostic and prognostic information. Certain chromosome abnormalities are hallmarks of specific blood cancers. For example, chronic myeloid leukemia (CML) is characterized by the Philadelphia chromosome, involving a translocation between chromosomes 9 and 22, while acute promyelocytic leukemia (APL/M3) is characterized by a translocation between chromosomes 15 and 17. Chromosome abnormalities can also provide important information about prognosis and relapse risk.

2. Can reveal broader, previously unsuspected abnormalities. Karyotyping gives a 'big-picture' view of the chromosomes. Even if the specific gene involved is not yet known, a structural chromosome change may still be visible.

Limitations

1. Results take time. Cells usually need to be cultured and allowed to divide before the chromosomes can be examined, so testing commonly takes about 7 to 14 days.

2. Interpretation is highly dependent on technical expertise. Chromosomes must be recognized and analyzed visually, so experienced laboratory staff are essential.

3. If malignant cells do not divide, the result may be falsely negative. Karyotyping requires cells to reach metaphase. If tumor cells do not divide well in culture, or too few of them divide, an abnormality may not be detected even when it is present.

4. Sensitivity is relatively low. Only a limited number of cells are analyzed. When malignant cells make up less than about 5% to 10% of the sample, abnormalities may be missed. For this reason, karyotyping is not well suited to MRD monitoring.

Method 5: FISH (Fluorescence In Situ Hybridization)

FISH can be thought of as a more targeted way to look for specific chromosome or gene-region abnormalities. Fluorescent probes are designed to bind to selected chromosome or gene locations, producing visible signals when the target is present or rearranged.

Advantages

1. Provides independent diagnostic and prognostic information. When a particular chromosome abnormality is already known to be clinically relevant, FISH can help confirm it.

2. Can detect abnormalities that are too small to distinguish clearly under a standard microscope. A targeted fluorescent probe may identify changes that conventional karyotyping cannot resolve.

3. Does not require dividing cells. Unlike karyotyping, FISH can be performed without waiting for cells to grow and enter mitosis.

4. More cells can be analyzed, improving sensitivity. Hundreds of cells can be reviewed in a single test, allowing a more representative estimate of how many cells carry the abnormality. For residual leukemia, FISH is generally more sensitive than conventional karyotyping.

5. Faster turnaround and somewhat less dependence on visual pattern recognition. Results are often available within 1 to 2 days, and the fluorescent signals can be directly counted.

6. Can sometimes be performed retrospectively. Previously prepared bone marrow slides or paraffin-embedded tissue sections may be suitable for FISH, which can help clarify or revisit a diagnosis.

Limitations

1. Probes are costly, and each probe usually tests only one or a small number of specific abnormalities.

2. FISH can only look for abnormalities the laboratory has chosen to target. The probe has to be designed for a known abnormality, so unexpected changes may be missed. In simple terms, karyotyping provides a broader overview, while FISH performs a focused search.

Method 6: Genetic Testing

Genetic testing looks at disease at the DNA and RNA level - for example, whether a gene carries a mutation or fusion, or whether a particular gene is being expressed at an abnormal level.

Advantages

1. Provides independent diagnostic and prognostic information. Many gene abnormalities can serve as disease-defining markers, including NPM1 mutations and biallelic CEBPA mutations. Molecular findings can also help refine risk classification.

2. Can detect abnormalities that chromosome analysis and FISH may miss. Some gene changes are too small to alter chromosome structure and are not covered by available FISH probes. Sequencing and other molecular methods can identify these changes. Combining chromosome analysis, FISH, and genetic testing can provide a more complete picture of prognosis.

3. Turnaround is generally shorter than conventional chromosome analysis for many molecular tests, with results often available within 1 to 2 weeks.

4. Results are somewhat less dependent on an individual observer's visual experience, provided the laboratory uses standardized procedures and strict quality control.

5. Can provide highly sensitive MRD monitoring for patients with trackable molecular markers. PCR or sequencing can follow specific mutations or fusion genes over time, with sensitivity reaching approximately 1 in 10,000 or even 1 in 100,000 cells in appropriate settings.

Limitations

1. Laboratory design, processing, and data analysis must be of very high quality. Molecular testing involves many steps and large amounts of data, so problems at any stage can affect accuracy.

2. It cannot diagnose every blood cancer on its own. Not all hematologic malignancies have a known or detectable driver abnormality, so morphology, flow cytometry, chromosome analysis, pathology, and other methods may still be essential.

At this point, you may be wondering: if all six tests have been completed, is that enough? Not always. Beyond these core laboratory tests within an integrated MICM evaluation, two other types of assessment may also be important during the course of care. One is pathogen testing, which helps determine whether viral or bacterial infections - such as Epstein-Barr virus (EBV) - are affecting the patient's condition. The other is therapeutic drug monitoring and pharmacogenetic testing, which can help doctors individualize medication use, improve effectiveness, and reduce toxicity risk.

The key point is that no single test can answer every question. Doctors need to integrate information from several dimensions to diagnose the disease more accurately, choose treatment, and assess response. Understanding what each test can and cannot tell you can also make the diagnostic and treatment process easier for patients and families to follow.

Disclaimer: Expert opinions are provided for general reference only. Please consult your treating physician for advice specific to your condition.